Low serum Vitamin D levels may contribute to gastric dysmotility in de novo Parkinson's disease

Neurodegenerative Diseases

Volumn 16, Issue 3-4, 2016, Pages 199-205

  Kwon, Ki Young ^a   Jo, Kwang Deog ^a   Lee, Moon Kyu ^a   Oh, Minyoung ^a   Kim, Eyu Nyong ^a   Park, Jinse ^f   Kim, Ji Sun ^d   Youn, Jinyoung ^e   Oh, Engseok ^g   Kim, Hee Tae ^c   Oh, Mi Young ^b   Jang, Wooyoung ^a,b  

^a University of Ulsan   (South Korea)

^b Department of Internal Medicine   (South Korea)

^c Hanyang University   (South Korea)

^d Soonchunhyang University   (South Korea)

^e Sungkyunkwan University   (South Korea)

^f Inje University College of Medicine   (South Korea)

^g Chungnam National University College of Medicine   (South Korea)

Author keywords

25 Hydroxyvitamin D 3; Gastric emptying time; Parkinson's disease; Vitamin D

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CALCIFEDIOL; CALCIUM; CREATININE; GHRELIN; PARATHYROID HORMONE; PENTETATE TECHNETIUM TC 99M;

ADULT; ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE SEVERITY; FEMALE; GASTRIC DYSMOTILITY; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMACH EMPTYING; UREA NITROGEN BLOOD LEVEL; VITAMIN BLOOD LEVEL; AGED; BLOOD; BLOOD ANALYSIS; CROSS-SECTIONAL STUDY; DIAGNOSTIC IMAGING; MENTAL HEALTH; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TIME FACTOR; VITAMIN D DEFICIENCY;

AGED; BLOOD CHEMICAL ANALYSIS; CALCIFEDIOL; CROSS-SECTIONAL STUDIES; FEMALE; GASTRIC EMPTYING; GHRELIN; HUMANS; MALE; MENTAL STATUS SCHEDULE; MULTIVARIATE ANALYSIS; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; VITAMIN D DEFICIENCY;

EID: 84953807047     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000441917     Document Type: Article

References (39)

1. Chaudhuri KR, Healy DG, Schapira AHV: Non-motor symptoms of Parkinson s disease: diagnosis and management. Lancet Neurol 2006; 5: 235-245
2. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464-474
3. Jang W, Park J, Shin KJ, Kim J-S, Kim JS, Youn J, Cho JW, Oh E, Ahn JY, Oh K-W et al. Safety and efficacy of recombinant human erythropoietin treatment of non-motor symptoms in Parkinson s disease. J Neurol Sci 2014; 337: 47-54
4. Cersosimo MG, Benarroch EE. Autonomic involvement in Parkinson s disease: pathology, pathophysiology, clinical features and possible peripheral biomarkers. J Neurol Sci 2012; 313: 57-63
5. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson s disease. Lancet Neurol 2003; 2: 107-116
6. Braak H, de Vos RAI, Bohl J, Del Tredici K. Gastric α-synuclein immunoreactive inclusions in Meissner s and Auerbach s plexuses in cases staged for Parkinson s disease-related brain pathology. Neurosci Lett 2006; 396: 67-72
7. Edwards LL, Pfeiffer RF, Quigley EMM, Hofman R, Balluff M. Gastrointestinal symptoms in Parkinson s disease. Mov Disord 1991; 6: 151-156
8. Jost WH. Gastrointestinal dysfunction in Parkinson s disease. J Neurol Sci 2010; 289: 69-73
9. Deleu D, Ebinger G, Michotte Y. Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson s disease with a fluctuating response to levodopa. Eur J Clin Pharmacol 1991; 41: 453-458
10. Djaldetti R, Baron J, Ziv I, Melamed E. Gastric emptying in Parkinson s disease: patients with and without response fluctuations. Neurology 1996; 46: 1051-1054
11. Cersosimo MG, Benarroch EE. Pathological correlates of gastrointestinal dysfunction in Parkinson s disease. Neurobiol Dis 2012; 46: 559-564
12. Sanger GJ, Lee K. Hormones of the gut-brain axis as targets for the treatment of upper gastrointestinal disorders. Nat Rev Drug Discov 2008; 7: 241-254
13. Ejskjaer N, Vestergaard ET, HellstrOM PM, Gormsen LC, Madsbad S, Madsen JL, Jensen TA, Pezzullo JC, Christiansen JS, Shaughnessy L,. et al. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther 2009; 29: 1179-1187
14. Wang L, Murphy NP, Stengel A, Goebel-Stengel M, Pierre DHS, Maidment NT, Tache Y. Ghrelin prevents levodopa-induced inhibition of gastric emptying and increases circulating levodopa in fasted rats. Neurogastroenterol Motil 2012; 24: e235-e245
15. Grant WB. Epidemiology of disease risks in relation to vitamin D insufficiency. Prog Biophys Mol Biol 2006; 92: 65-79
16. Annweiler C, Beauchet O. Possibility of a new anti-Alzheimer s disease pharmaceutical composition combining memantine and vitamin D. Drugs Aging 2012; 29: 81-91
17. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1α-hydroxylase in human brain. J Chem Neuroanat 2005; 29: 21-30
18. Jang W, Kim HJ, Li H, Jo KD, Lee MK, Song SH, Yang HO. 1, 25-Dihydroxyvitamin D 3 attenuates rotenone-induced neurotoxicity in SH-SY5Y cells through induction of autophagy. Biochem Biophys Res Commun 2014; 451: 142-147
19. Jang W, Park H-H, Lee K-Y, Lee Y, Kim H-T, Koh S-H: 1, 25-Dihydroxyvitamin D 3 attenuates L -dopa-induced neurotoxicity in neural stem cells. Mol Neurobiol 2015; 51: 558-570
20. Sanchez B, Relova JL, Gallego R, Ben-Batalla I, Perez-Fernandez R. 1, 25-Dihydroxyvitamin D 3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum. J Neurosci Res 2009; 87: 723-732
21. Smith M, Fletcher-Turner A, Yurek D, Cass W. Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine. Neurochem Res 2006; 31: 533-539
22. Newmark HL, Newmark J. Vitamin D and Parkinson s disease - A hypothesis. Mov Disord 2007; 22: 461-468
23. Jang W, Park J, Kim J, Youn J, Oh E, Kwon K, Jo K, Lee M, Kim HT. Vitamin D deficiency in Parkinson s disease patients with orthostatic hypotension. Acta Neurol Scand 2015; 132: 242-250
24. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I. Variable expression of Parkinson s disease: a base-line analysis of the DAT ATOP cohort. Neurology 1990; 40: 1529-1529
25. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol 2009; 19: 73-78
26. van den Ouweland JW, Vogeser M, Bacher S. Vitamin D and metabolites measurement by tandem mass spectrometry. Rev Endocr Metab Disord 2013; 14: 159-184
27. Kedar A, Nikitina Y, Henry OR, Abell KB, Vedanarayanan V, Griswold ME, Subramony C, Abell TL. Gastric dysmotility and low serum vitamin D levels in patients with gastroparesis. Horm Metab Res 2013; 45: 47-53
28. Tanaka Y, Kato T, Nishida H, Yamada M, Koumura A, Sakurai T, Hayashi Y, Kimura A, Hozumi I, Araki H,. et al. Is there a delayed gastric emptying of patients with early-stage, untreated Parkinson s disease?. An analysis using the 13 C-acetate breath test. J Neurol 2011; 258: 421-426
29. Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F. Parkinson s disease: the presence of Lewy bodies in Auerbach s and Meissner s plexuses. Acta Neuropathol 1988; 76: 217-221
30. Peterson AL, Mancini M, Horak FBàrelationship between balance control and vitamin D in Parkinson s disease - A pilot study. Mov Disord 2013; 28: 1133-1137
31. Guo L, Chen W, Zhu H, Chen Y, Wan X, Yang N, Xu S, Yu C, Chen L. Helicobacter pylori induces increased expression of the vitamin D receptor in immune responses. Helicobacter 2014; 19: 37-47
32. Suzuki H, Moayyedi P. Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013; 10: 168-174
33. Saito Y, Suzuki H, Tsugawa H, Suzuki S, Matsuzaki J, Hirata K, Hibi T. Dysfunctional gastric emptying with down-regulation of muscle-specific microRNAs in Helicobacter pylori -infected mice. Gastroenterology 2011; 140: 189-198
34. Chang CS, Chen GH, Kao CH, Wang SJ. Delayed gastric emptying does not predispose to Helicobacter pylori infection in non-ulcer dyspepsia patients. Nucl Med Commun 1995; 16: 1063-1067
35. Miyaji, Azuma, Ito, Abe, Ono, Suto, Yamazaki, Kohli, Kuriyama: The effect of Helicobacter pylori eradication therapy on gastric antral myoelectrical activity and gastric emptying in patients with non-ulcer dyspepsia. Aliment Pharmacol Therapeut 1999; 13: 1473-1480
36. Evans M, Triggs E, Cheung M, Broe G, Creasey H. Gastric emptying rate in the elderly: implications for drug therapy. J Am Geriatr Soc 1981; 29: 201-205
37. Goetze O, Nikodem A, Wiezcorek J, Banasch M, Przuntek H, Mueller T, Schmidt W, Woitalla D. Predictors of gastric emptying in Parkinson s disease. Neurogastroenterol Motil 2006; 18: 369-375
38. Robertson GS, Jagger C, Johnson PR, Rathbone BJ, Wicks AC, Lloyd DM, Veitch PS. Selection criteria for preoperative endoscopic retrograde cholangiopancreatography in the laparoscopic era. Arch Surg 1996; 131: 89-94
39. Hardoff R, Sula M, Tamir A, Soil A, Front A, Badarna S, Honigman S, Giladi N. Gastric emptying time and gastric motility in patients with Parkinson s disease. Mov Disord 2001; 16: 1041-1047